Recommendable! At least the study confirmed that treatment with LSD microdosing is safe! 😊
What is microdosing anyway? If the dose is small enough it may not have an effect at all. It becomes a placebo.
"A landmark clinical trial testing the effect of microdosing LSD on symptoms of attention-deficit hyperactive disorder (ADHD) recently delivered its first data readout and the results have been surprising, to say the least, raising questions over the efficacy of this popular trend. ...
Despite this massive wealth of anecdotal evidence, robust clinical research into microdosing has been minimal. The very few placebo-controlled examinations conducted on the practice have pretty consistently struggled to find any effect at all.
The latest clinical trial to test the practice has focused on the effect of microdosing LSD for symptoms of ADHD. The trial is the first to test microdosing in a cohort of patients suffering from a specific condition. Prior trials have mostly focused on mood effects in healthy cohorts or groups with sub-clinical mental health problems. The new trial is also one of the longest and most robust investigations into the popular phenomenon ever conducted. ...
The trial recruited 53 participants, all fitting the diagnostic criteria for moderate to severe ADHD. Half were given LSD microdoses of 20 micrograms, and the other half were given a placebo. All were administered doses twice a week for six weeks.
At the end of the study period all participants showed statistically significant reductions in their ADHD symptoms, regardless of placebo or LSD. In fact, the placebo group displayed marginally greater symptomatic improvements, although that difference was considered statistically insignificant. ..."
From the key points and abstract:
"Key Points
Question
Does twice-weekly low-dose (20 μg) lysergic acid diethylamide (LSD) over 6 weeks reduce symptoms of attention-deficit/hyperactivity disorder (ADHD) in adults with moderate to severe ADHD compared with placebo?
Findings
In this multicenter, double-blind, placebo-controlled randomized clinical trial in 53 individuals, both the LSD and placebo groups exhibited a significant reduction of ADHD symptoms. However, there was no difference in symptom reduction between the 2 groups.
Meaning
LSD was not efficacious in reducing ADHD symptoms compared with placebo; these results question the anecdotal practice and highlight the importance of placebo-controlled trials in low-dose psychedelic research.
Abstract
Importance
Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD’s efficacy in reducing ADHD symptoms remains unknown.
Objective
To determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with placebo.
Design, Setting, and Participants
This was a 6-week, multicenter, double-blind, placebo-controlled, parallel-group phase 2A randomized clinical trial conducted between December 17, 2021, and December 4, 2023. Data were analyzed from March 22, 2024, to August 19, 2024. Outpatient treatment was provided at 2 centers: University Hospital in Basel, Switzerland, and Maastricht University in the Netherlands. Adults aged 18 to 65 years with a prior ADHD diagnosis who presented with moderate to severe symptoms (Adult Investigator Symptom Rating Scale [AISRS] score ≥26 and Clinical Global Impression Severity score ≥4) were eligible for inclusion. Key exclusion criteria included selected current major psychiatric or somatic disorders and the use of potentially interacting medications.
Intervention Participants received either LSD (20 μg) or placebo twice weekly for 6 weeks (total of 12 doses).
Main Outcome and Measures The primary outcome was the change in ADHD symptoms from baseline to week 6, assessed by the AISRS and analyzed with a mixed-effects model for repeated measures.
Results
A total of 53 participants were randomized to LSD (n = 27) or placebo (n = 26). Mean (SD) participant age was 37 (12) years, and 22 participants (42%) were female.
The LSD group presented a mean AISRS improvement of −7.1 points (95% CI, −10.1 to −4.0).
The placebo group presented a mean AISRS improvement of −8.9 points (95% CI, −12.0 to −5.8), with no difference between groups. LSD was physically safe and psychologically well tolerated overall.
Conclusions and Relevance
In this randomized clinical trial, repeated low-dose LSD administration was safe in an outpatient setting, but it was not more efficacious than placebo in reducing ADHD symptoms."
No comments:
Post a Comment